10000 Participants Needed

Colchicine + Aspirin for Cardiovascular Disease in Type 2 Diabetes

(COLCOT-T2D Trial)

JT
MP
Overseen ByMylène Provencher, PhD
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I have to stop taking my current medications to join the trial?

The trial does not specify a general requirement to stop all current medications. However, if you are currently using aspirin, another antiplatelet agent, an anticoagulant, or colchicine for other conditions, you may not be eligible for certain parts of the trial. There is no wash-out period required for colchicine if you stop before enrolling. Please consult with the trial team for specific guidance based on your medications.

What data supports the idea that Colchicine + Aspirin for Cardiovascular Disease in Type 2 Diabetes is an effective drug?

The available research shows that aspirin, when used alone, can help reduce the risk of heart attacks and strokes in people with diabetes, although the benefits are smaller compared to those with a history of heart disease. However, aspirin also increases the risk of stomach bleeding. The studies suggest that aspirin is less effective in diabetic patients compared to non-diabetic ones, possibly due to greater aspirin resistance in diabetics. There is no specific data provided on the combination of Colchicine and Aspirin for cardiovascular disease in type 2 diabetes, so it's unclear how effective this combination is compared to aspirin alone or other treatments.12345

What safety data exists for using Colchicine and Aspirin in treating cardiovascular disease in type 2 diabetes?

The provided research primarily focuses on the safety and efficacy of aspirin (acetylsalicylic acid) in diabetic patients for cardiovascular prevention. It highlights that aspirin is generally considered safe and effective for reducing cardiovascular risk, though it may have different effects based on gender and may require higher dosages in diabetic patients due to aspirin resistance. However, there are concerns about gastrointestinal bleeding risks, especially in elderly diabetic patients. The long-term safety of low-dose aspirin remains inconclusive. There is no specific safety data on the combination of Colchicine and Aspirin in the provided research.12678

Is aspirin a promising drug for preventing heart disease in people with type 2 diabetes?

Aspirin is considered a helpful drug for preventing heart disease in people with type 2 diabetes, especially for those who already have heart problems. It is recommended by international guidelines for reducing heart-related issues in diabetic patients.1291011

What is the purpose of this trial?

This trial is testing colchicine and non-coated aspirin, alone or together, to help high-risk type 2 diabetes patients avoid heart problems. Colchicine reduces inflammation, and aspirin helps prevent blood clots.

Eligibility Criteria

This trial is for men and women aged 55 to 80 with type 2 diabetes, without a history of significant heart disease. Participants must not be pregnant or planning pregnancy, should agree to use birth control if applicable, and cannot have severe kidney issues or be on certain medications like chronic steroids or anticoagulants.

Inclusion Criteria

Active cigarette smoking
HbA1c ≥ 8.0% or more in the last 2 years
I have had a stroke or surgery due to severe narrowing of my brain's blood vessels.
See 17 more

Exclusion Criteria

My muscle enzyme levels are more than three times the normal limit and have been confirmed by repeat tests.
My kidney function is low, with an eGFR below 35 mL/min/1.73m2.
I am on long-term medication for inflammation, such as anti-TNF or NSAIDs.
See 15 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes

60 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Aspirin
  • Colchicine
Trial Overview The study tests the effectiveness and safety of colchicine and non-enteric coated aspirin, alone or together, in improving heart health outcomes for those at high risk due to type 2 diabetes. It's a comparison between these drugs and their placebos.
Participant Groups
4Treatment groups
Active Control
Placebo Group
Group I: Anti-thrombotic armActive Control4 Interventions
For patients eligible for aspirin therapy arm.
Group II: Anti-inflammatory armActive Control2 Interventions
For patients ineligible for aspirin therapy arm.
Group III: Anti-inflammatory arm (Placebo)Placebo Group2 Interventions
For patients ineligible for aspirin therapy arm.
Group IV: Anti-thrombotic arm (Placebo)Placebo Group4 Interventions
For patients eligible for aspirin therapy arm.

Aspirin is already approved in European Union, United States, Canada, China for the following indications:

🇪🇺
Approved in European Union as Aspirin for:
  • Pain relief
  • Fever reduction
  • Inflammation
  • Cardiovascular disease prevention
  • Preeclampsia prevention
🇺🇸
Approved in United States as Aspirin for:
  • Pain relief
  • Fever reduction
  • Inflammation
  • Cardiovascular disease prevention
  • Preeclampsia prevention
🇨🇦
Approved in Canada as Aspirin for:
  • Pain relief
  • Fever reduction
  • Inflammation
  • Cardiovascular disease prevention
  • Preeclampsia prevention
🇨🇳
Approved in China as Aspirin for:
  • Pain relief
  • Fever reduction
  • Inflammation
  • Cardiovascular disease prevention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Montreal Heart Institute

Lead Sponsor

Trials
125
Recruited
85,400+

Findings from Research

In a study of diabetic patients within the Department of Veterans Affairs, 71% reported receiving counseling about aspirin use, and 66% were taking it daily, indicating improved awareness and usage compared to the early 1990s.
Counseling by healthcare providers was the strongest predictor of aspirin use, and increasing daily aspirin use to 90% could potentially prevent 11,000 myocardial infarctions and save over 8,000 lives, highlighting the importance of this intervention in diabetes care.
Aspirin use and counseling about aspirin among patients with diabetes.Krein, SL., Vijan, S., Pogach, LM., et al.[2019]
Aspirin is effective as an antiplatelet therapy for preventing cardiovascular diseases, but its efficacy varies by gender and population, showing more coronary event reduction in men and stroke reduction in women.
In diabetic patients, aspirin may offer less protection against cardiovascular complications compared to non-diabetic individuals, and there is a suggestion of increased aspirin resistance, potentially requiring higher dosages for effective prevention.
[Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].Legrand, DA., Scheen, AJ.[2015]
A systematic review of 7 trials involving 11,618 individuals with diabetes found that aspirin therapy did not significantly reduce major cardiovascular events or all-cause mortality, indicating limited efficacy for primary prevention in this population.
Despite the lack of overall benefit, the analysis suggested that aspirin may have sex-specific effects, potentially reducing the risk of stroke in women and myocardial infarction in men, without significantly increasing the risk of major bleeding.
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.Zhang, C., Sun, A., Zhang, P., et al.[2013]

References

Aspirin use and counseling about aspirin among patients with diabetes. [2019]
[Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. [2015]
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. [2013]
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. [2023]
Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. [2022]
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. [2023]
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. [2020]
Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes. [2014]
Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study. [2023]
Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings. [2022]
[Factors that influence the implementation of the guidelines for aspirin use by diabetic patients in Israel]. [2013]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security